- AptarGroup Sets CEO Succession as 2025 Sales Rise and Shareholders Back Ballot
May 9, 2026
AptarGroup logo
Key Points
Interested in AptarGroup, Inc.? Here are five stocks we like better. CEO transition announced: AptarGroup CEO Stephan Tanda plans to retire on Sept. 1, 2026, and Gael Touya, currently head of Aptar Pharma, will take over as president and CEO. Tanda will stay on as an adviser through year-end to help ensure a smooth handoff. Shareholders approved all ballot items: At the annual meeting, investors elected four directors, approved executive compensation on an advisory basis, and ratified PricewaterhouseCoopers as Aptar’s 2026 auditor. No shareholder nominations or other motions were presented. 2025 results and outlook were solid: Aptar reported 5% sales growth to $3.8 billion in 2025, with Pharma leading segment growth and the company returning $486 million to shareholders through buybacks and dividends. Management said first-quarter 2026 sales were up 11% reported, while long-term targets remain unchanged.
AptarGroup (NYSE:ATR) used its annual meeting to announce a planned chief executive transition, report that shareholders approved all items on the ballot and provide an update on 2025 performance and early 2026 results.
President and Chief Executive Officer Stephan Tanda told shareholders that he plans to retire after nearly 10 years in the role. Gael Touya, currently president of Aptar Pharma and a company veteran of more than 30 years, will become president and CEO on Sept. 1, 2026.
→ Light Speed Returns: Corning Cashes In on NVIDIA Growth
Tanda said he will remain in his current role until the transition date and then serve as an adviser through the end of the year to support a smooth handoff. He also said he expects to retire from the board at year-end, while the board expects to appoint Touya as a director on Sept. 1, 2026.
Touya said he was “privileged” to step into the role and thanked Tanda for his leadership, adding that Aptar has been his “professional home” for more than 30 years.
Shareholders Approve Directors, Compensation and Auditor
→ Uber's Annual Product Showcase Reveals It Is Coming for Airbnb and Booking
Irene Hudson, executive vice president, chief legal officer and secretary, said a quorum was present at the virtual-only meeting. She said the company had not received notice of any shareholder nominations or other motions, leaving only the matters listed in the annual meeting notice for consideration.
Based on the preliminary vote count, shareholders elected four directors to serve until the 2029 annual meeting: George L. Fotiades, Candace Matthews, B. Craig Owens and Julie Xing. Shareholders also approved, on an advisory basis, Aptar’s executive compensation and ratified PricewaterhouseCoopers LLP as the company’s independent registered public accounting firm for 2026.
Story Continues
→ Wells Fargo’s Comeback Is Real—But Not Risk-Free
Tanda declared each proposal approved after the inspector of election reported that the required votes had been cast in favor of the nominees and the other ballot items. No shareholder questions were submitted during the question-and-answer portion of the meeting, according to Mary Scafidas, senior vice president of investor relations and communications.
2025 Sales Rise 5%
After the formal meeting adjourned, Tanda reviewed the company’s business performance and recent results. He said 2025 was driven by Aptar’s purpose to “innovate and transform ideas into solutions that improve everyday life,” pointing to technologies that deliver medications, add convenience and security for consumers, and support recyclability, reusability and sustainability.
For 2025, reported sales increased 5% to $3.8 billion from $3.6 billion in the prior year. Core sales rose 2%, which Tanda said reflected steady demand across key product categories. The company returned $486 million to shareholders through share repurchases and dividends during the year. Tanda also noted that 2025 marked Aptar’s 32nd consecutive year of paying an annually increasing dividend.
Pharma Leads Segment Growth
Tanda highlighted the strength and diversity of the company’s Pharma pipeline, citing a growing number of systemic nasal drug delivery projects and increased participation in injectable projects, including projects for GLP-1 and NX-1. The Pharma segment reported sales growth of 6% in 2025 to $1.74 billion, driven by strong demand for emergency medicine and central nervous system products as well as higher royalties.
In the Beauty segment, reported sales increased 7% in 2025 to $1.31 billion, with currency and acquisitions contributing positively and core sales showing modest growth. The Closures segment reported sales growth of 2% to $730.3 million, including a currency benefit and slight core sales growth.
Capital Allocation and 2026 Outlook
Tanda said Aptar has focused on investing in higher-returning and faster-growing businesses, especially Pharma, while remaining committed to returning capital to shareholders. Over the past five years, the company has returned $1.2 billion to shareholders through dividends and share repurchases.
For the first quarter of 2026, Tanda said reported sales increased 11%, while core sales, adjusted for currency effects and acquisitions, were flat compared with the prior year.
He also emphasized safety, employee engagement, leadership development and community involvement. Tanda said the company’s goal of zero injuries remains a top priority and noted continued expansion of Aptar’s Corporate University.
Aptar’s long-term financial targets remain unchanged, including an adjusted EBITDA margin target of 21% to 23% and an overall core sales growth target of 4% to 7%. Tanda said the company intends to continue executing a productivity roadmap aimed at addressing short-term headwinds and improving efficiency across operations, supply chains and selling, general and administrative expenses.
“In closing, 2025 was a strong year, and we are well-positioned for broad-based growth across all three of our segments,” Tanda said. He added that Aptar’s balance sheet provides the company with the ability to invest for the future, return capital to shareholders and maintain flexibility for strategic opportunities.
About AptarGroup (NYSE:ATR)
AptarGroup, Inc is a global provider of advanced dispensing, sealing and protection solutions for consumer and pharmaceutical markets. The company designs and manufactures a broad portfolio of products that enable the controlled delivery of liquids, gels, powders and aerosols. Its customer base spans beauty and personal care, home care, food and beverage, and pharmaceutical sectors, where innovation in packaging and drug‐delivery devices drives brand differentiation and regulatory compliance.
In the consumer markets, AptarGroup offers pumps, actuators, valves, closures and specialized bottles engineered for precision, convenience and sustainability.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
The article "AptarGroup Sets CEO Succession as 2025 Sales Rise and Shareholders Back Ballot" was originally published by MarketBeat.
View MarketBeat's top stocks for May 2026.
View Comments
- AptarGroup Sets CEO Succession as 2025 Sales Rise and Shareholders Back Ballot
May 9, 2026 · marketbeat.com
AptarGroup NYSE: ATR used its annual meeting to announce a planned chief executive transition, report that shareholders approved all items on the ballot and provide an update on 2025 performance and early 2026 results.
- Top Research Reports for Eli Lilly, Western Digital & Vertiv
May 6, 2026
Wednesday, May 6, 2026
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Co. (LLY), Western Digital Corp. (WDC) and Vertiv Holdings Co (VRT), as well as a micro-cap stock AgEagle Aerial Systems, Inc. (UAVS). The Zacks microcap research is unique as our research content on these small and under-the-radar companies is the only research of its type in the country.
These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Ahead of Wall Street
The daily 'Ahead of Wall Street' article is a must-read for all investors who would like to be ready for that day's trading action. The article comes out before the market opens, attempting to make sense of that morning's economic releases and how they will affect that day's market action. You can read this article for free on our home page and can actually sign up there to get an email notification as this article comes out each morning.
You can read today's AWS here >>> ADP +109K: Job Growth on Lower-Paying Work
Today's Featured Research Reports
Eli Lilly’s shares have outperformed the Zacks Large Cap Pharmaceuticals industry over the past year (+28.2% vs. +21.5%). The company’s Q1 earnings and sales beat estimates. Demand for its popular GLP-1 drugs Mounjaro and Zepbound remains strong, making them the company’s key top-line drivers.
Lilly’s other new drugs like Kisunla, Omvoh and Jaypirca are also contributing to top-line growth. It is also making rapid pipeline progress in obesity and diabetes with its new oral GLP-1 obesity pill, Foundayo, expected to be a commercial game-changer for Lilly.
Over the past couple of years, Lilly has announced several M&A deals aimed at diversifying beyond GLP-1 drugs and expanding its presence in cardiovascular, oncology, and neuroscience. Declining sales of Trulicity, rising pricing pressure on some drugs and potential competition in the GLP-1 market are some top-line headwinds.
(You can read the full research report on Eli Lilly here >>>)
Shares of Western Digital have outperformed the Zacks Computer- Storage Devices industry over the past year (+952.5% vs. +568.9%). The company’s fiscal third-quarter results were led by strength across end markets riding on AI-led storage needs and multi-year customer agreements extending through 2028-29. Cloud end market (89% of total) rose 48% to $3B, fueled by strong demand for high-capacity nearline drives and favorable pricing.
Margins were driven by higher-capacity drives and higher UltraSMR uptake that improved customer TCO, while strong operating leverage, lower interest costs and tax efficiency led to double EPS. WD is advancing areal density and enhancing performance with high-bandwidth drives.
Western Digital strengthened balance sheet by selling 5.8 million SanDisk shares, cutting debt by $3.1 billion, leaving $1.6 billion in convertible debt and ending with a $450 million net cash position. WD expects fiscal fourth-quarter revenue of $3.65B, up 40% year-over-year at the midpoint.
(You can read the full research report on Western Digital here >>>)
Vertiv’s shares have outperformed the Zacks Computers - IT Services industry over the past year (+265.6% vs. -26.4%). The company remains leveraged to rising data center power and thermal needs as AI deployments drive higher infrastructure density and faster build cycles. Q1’26 results showed continued demand and execution, with organic sales growth led by the Americas and higher profitability supported by productivity and price-cost.
Management raised 2026 guidance and is investing in capacity, services, and engineering, while acquisitions extend capabilities in liquid cooling and heat rejection. A strengthened balance sheet following investment-grade ratings and refinancing supports this investment cycle.
Against these positives, regional volatility persists, with EMEA still working through prior order softness and APAC exposed to uneven China demand. Tariffs and supply chain complexity also require ongoing mitigation to protect margins.
(You can read the full research report on Vertiv here >>>)
Shares of AgEagle Aerial Systems have gained +21.3% over the past year against the Zacks Agriculture - Operations industry’s gain of +30.7%. This microcap company with a market capitalization of $61.69 million is positioned to benefit from regulatory approvals, defense adoption, and a broad global distribution network that support growth in commercial and government drone markets.
AgEagle Aerial Systems’ integrated drone-and-sensor ecosystem, expanding multispectral imaging portfolio, and manufacturing expansion strengthen its ability to serve higher-value applications and benefit from increasing demand for compliant, domestically sourced systems. The company also benefits from an established operating history and large installed base, supporting credibility in mission-critical use cases.
However, key risks remain tied to inconsistent revenue growth, ongoing operating losses, and dependence on external financing. Revenue visibility is limited by customer concentration and uneven procurement cycles, while the lack of meaningful recurring revenue keeps results tied to hardware sales.
(You can read the full research report on AgEagle Aerial Systems here >>>)
Other noteworthy reports we are featuring today include Chipotle Mexican Grill, Inc. (CMG), Reddit, Inc. (RDDT) and First Solar, Inc. (FSLR).
Mark Vickery
Senior Editor
Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>
Story Continues
Today's Must Read
Lilly (LLY) New Drugs to Drive Sales Growth Amid Rising Competition
Western Digital (WDC) Poised for Growth on AI Storage and HDD Demand
AI-Driven Data Center Demand Aids Vertiv (VRT) Prospects
Featured Reports
Chipotle (CMG) Banks On Strategic Initiatives, High Costs Ail
Per the Zacks analyst, Chipotle's focus on Recipe for Growth strategy, unit expansion, and Zipline pilot bode well. However, the uncertain macro environment and high costs pose concerns.
Strong Solar Demand Aids First Solar (FSLR) Amid Tariff Risks
Per the Zacks analyst, First Solar is benefiting from strong solar demand, though rising tariffs and trade uncertainties across key manufacturing regions may pressure near-term operations and costs.
Murphy USA (MUSA) Benefits from a High-Volume, Low-Cost Model
The Zacks analyst believes that Murphy USA's high-volume, low-cost model, along with its proximity to Walmart, positions the company to maintain above-average fuel sales and strong profitability.
Encompass Health (EHC) Strengthens Growth Through Expansion Efforts
Per the Zacks analyst, Encompass Health's expansion through de novo hospitals will drive patient volumes and profit levels. However, escalating expenses remain a concern for the company.
Healthcare Demand Aids AptarGroup (ATR) Amid Soft Closures Volumes
Per the Zacks analyst, AptarGroup will gain from demand in consumer healthcare. However, weaker volumes and pricing dynamics in Closures remain a woe.
Leisure Demand and Strategic Initiatives Aid Marriott Vacations (VAC)
Per the Zacks analyst, Marriott Vacations benefits from resilient leisure demand and improving rental and financing trends. Also, focus on operational initiatives and asset monetization bode well.
Cost Management Approach, Stable Solvency Boost Omnicell (OMCL)
The Zacks analyst is impressed with Omnicell's expense containment measures that aggravates non-GAAP EBITDA expansion. Also, a strong solvency looks encouraging.
New Upgrades
Reddit (RDDT) Rides on Growing User Engagement, AI Features
Per the Zacks analyst, Reddit is benefiting from strong growth in user engagement driven by AI-powered features.
Silicon Motion (SIMO) Rides on Strength in Multiple Verticals
Per the Zacks analyst, growing demand across embedded storage, automotive, and emerging AI-driven enterprise applications will likely drive Silicon Motion's top line.
Helen of Troy (HELE) Gains on Strength in Leadership Brands
Per the Zacks analyst, Helen of Troy is benefiting from strong performance in its Leadership Brands, with growth in key categories, improved pricing and continued innovation supporting its outlook.
New Downgrades
Grab is Hurt By Labor Issue Stiff Competition and Economic Uncertainty
Per the Zacks Analyst, stiff competition from regional players, economic uncertainty in Southeast Asian markets like Singapore and the Philippines, and labor crisis hurt Grab's prospects.
Cat Loss Exposure, Rising Expenses Hurt CNA Financial (CNA)
Per the Zacks analyst, CNA Financial's exposure to catastrophe loss induces underwriting volatility thus profitability while rising expenses affecting net operating income concerns.
Rising Expenses, Geopolitical Woes to Hurt Moelis and Company (MC)
Per the Zacks analyst, higher costs due to Moelis and Company's hiring spree and investments in technology will hurt profits. Geopolitical and macroeconomic woes add to ambiguity in operating backdrop
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
First Solar, Inc. (FSLR) : Free Stock Analysis Report
Eli Lilly and Company (LLY) : Free Stock Analysis Report
Western Digital Corporation (WDC) : Free Stock Analysis Report
Chipotle Mexican Grill, Inc. (CMG) : Free Stock Analysis Report
AGEAGLE AERIAL SYSTEMS, INC. (UAVS): Free Stock Analysis Report
Vertiv Holdings Co. (VRT) : Free Stock Analysis Report
Reddit Inc. (RDDT) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
View Comments
- Aptar Advances Sustainability Features in Luxury Packaging through Patented Reloadable Airless Innovation with Clarins
May 6, 2026
Aptar Advances Sustainability Features in Luxury Packaging through Patented Reloadable Airless Innovation with Clarins.
Innovation wins 2026 DIELINE Award with Clarins Total Eye Lift for ‘Sustainable Design – Health, Body & Beauty’
CRYSTAL LAKE, Ill, May 06, 2026--(BUSINESS WIRE)--AptarGroup, Inc. (NYSE: ATR), a global leader in drug delivery, dosing and protection technologies, and consumer product dispensing, today highlighted how its patented, high performance airless dispensing innovation is enabling prestige beauty brands to advance sustainability without compromising performance or luxury.
Through a long‑standing partnership with Clarins, Aptar developed a custom, reloadable airless packaging solution for Clarins Total Eye Lift Eye Cream, designed to enhance formula protection, dispensing precision and consumer experience. Each reload purchased reduces the material impact of the packaging by 73% due to 50% less metal, 33% less plastic and 29% less cardboard used in the component compared to the previous Total Eye Lift packaging1.
The collaboration reflects a shared ambition to integrate sustainability into the core of product design, supported by proprietary technology and customer‑specific engineering.
The Clarins Total Eye Lift packaging solution has received industry recognition for its design, execution and innovation in 2025 with a Formes de Luxe Award in the Dispensing Category. Most recently, Aptar Beauty was awarded First Place at the 2026 DIELINE Awards in the Sustainable Design – Health, Body & Beauty category, recognizing the innovation’s reloadable design, material efficiency and execution. The award was presented at Luxe Pack New York and evaluated across criteria including Creativity, Marketability, Innovation, Execution and On‑Pack Branding.
Patented Airless Technology Designed for Performance and Circularity
At the heart of these award‑winning solutions is Aptar Beauty’s patented Gaïa reloadable airless technology, with a custom outer casing to support Clarins’ sustainability objective to create a reloadable solution while preserving formula integrity, dispensing precision and elevated aesthetics.
Developed specifically for Clarins Total Eye Lift, this solution combines a premium metal outer casing with plastic reloads, designed to significantly reduce material usage while preserving a luxury look and feel. Its sleek, seamless design conceals technical components within the main casing, enabling refined, minimalist reloads. This solution is protected by two Aptar patents – one covering the intuitive push-and-pull reload mechanism, inspired by a ballpoint pen, and another covering a double tamper seal system designed to help optimize formula protection and helping to prevent contamination.
Story Continues
"This recognition reflects our dedication to advancing product circularity through refillable and recyclable solutions, developed in close partnership with customers who share our vision for sustainable innovation," said Ryan Kenny, President of Aptar Beauty North America.
A Benchmark for Customization and Sustainable Design
By pairing technical innovation with customer‑centric design, Aptar and Clarins demonstrate that sustainability and luxury are not mutually exclusive. The Total Eye Lift packaging enhances performance, supports product circularity and elevates the consumer experience – while reinforcing shelf differentiation and brand equity in the ultra‑competitive luxury skincare market.
"These recognitions highlight the strength of our partnership with Clarins and our shared commitment to pushing the boundaries of packaging innovation," said Xavier Joseph, Vice President, Global Marketing and Innovation, Aptar Beauty. "This project showcases how custom‑engineered, high‑performance solutions can deliver both sustainability features and premium value for our customers."
About Aptar
Aptar is a global leader in drug delivery, dosing and protection technologies, and consumer product dispensing. Aptar partners with the world’s top healthcare and consumer brands to deliver medicines and create exceptional user experiences. Serving diverse markets, from pharmaceutical to beauty to food and beverage, Aptar combines market expertise with proprietary design, engineering and science to develop innovative solutions that help improve lives worldwide. Headquartered in Crystal Lake, Illinois, Aptar employs 14,000 dedicated people across 20 countries. Learn more at http://www.aptar.com.
This press release contains forward-looking statements, including with regard to Aptar’s patented Gaïa reloadable airless technology and custom reloadable airless packaging solutions; the expected ability of these solutions to support sustainability objectives, material reduction, product circularity, formula protection, dispensing precision and consumer experience; market acceptance, commercial opportunities and consumer impact of such technology and products. Forward-looking statements generally can be identified by the fact that they do not relate strictly to historical or current facts and by use of words such as "expects," "anticipates," "believes," "estimates," "future," "potential," "continues" and other similar expressions or future or conditional verbs such as "will," "should," "would" and "could" are intended to identify such forward-looking statements. Forward-looking statements are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are based on our beliefs as well as assumptions made by and information currently available to us. Accordingly, our actual results or other events may differ materially from those expressed or implied in such forward-looking statements due to known or unknown risks and uncertainties that exist in our operations and business environment including, but not limited to: demand for and market acceptance of new products and technologies; customer and consumer preferences; our ability to develop, commercialize, manufacture and protect our technologies and products; product performance, quality or supply chain matters; the successful integration of acquisitions; the regulatory environment; and competition, including technological advances. For additional information on these and other risks and uncertainties, please see our filings with the Securities and Exchange Commission, including the discussion under "Risk Factors" and "Management’s Discussion and Analysis of Financial Condition and Results of Operations" in our Form 10-K and Form 10-Qs. We undertake no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
1 By refilling the bottle once: comparison between 2 full Total Eye Lift bottles and 1 full bottle refilled once. Based on a single score, calculated using a lifecycle analysis. Source: clarins.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20260506201869/en/
Contacts
Investor Relations Contact:
Mary Skafidas
Mary.skafidas@aptar.com
+1 347-351-6407
Media Contact:
Katie Reardon
Katie.reardon@aptar.com
+1 815-479-5671
View Comments
- AptarGroup Q1 Earnings Beat Estimates but Decline Y/Y, Shares Dip 1%
May 6, 2026
Shares of AptarGroup, Inc. ATR have dipped 1% since posting first-quarter 2026 adjusted earnings of $1.19 per share on Thursday. Adjusted earnings declined 8% from $1.30 a year ago on a less favorable mix and pharma-related headwinds. However, the bottom line topped the Zacks Consensus Estimate of $1.15.
Quarterly sales rose 10.8% year over year to $983 million and beat the consensus mark of $964 million by 2%.
AptarGroup, Inc. Price, Consensus and EPS Surprise
AptarGroup, Inc. price-consensus-eps-surprise-chart | AptarGroup, Inc. Quote
ATR’s Pharma Results Reflect Destocking Headwinds
Pharma segment sales increased 7.1% year over year to $439 million. The reported figure missed our estimate of $454 million. The reported gain was aided by currency and a small acquisition contribution, while core sales slipped 1% on tougher comparisons in the prescription business.
Within Pharma, prescription core sales declined 10% as dispensing systems tied to emergency medicine were pressured by destocking. Offsetting this, consumer healthcare core sales increased 4% on nasal decongestant and eye-care solutions, while injectables delivered 20% core growth.
The Pharma segment posted adjusted EBITDA of $146 million compared with the prior-year quarter’s $142 million. We predicted adjusted EBITDA of $140 million for the segment.
AptarGroup’s Beauty Benefits From Fragrance Demand
The Beauty segment’s sales advanced 19% year over year to $364 million. The reported figure beat our estimate of $324 million. Core sales grew 3% as demand improved across fragrance dispensing and select personal care applications, with acquisitions and currency providing additional lift.
Profitability in Beauty was softer despite sales growth. Adjusted EBITDA came in at $40 million compared with the prior-year quarter’s $37 million. We predicted adjusted EBITDA of $34.5 million for the segment.
ATR’s Closures Sees Pricing Offset Volume Gains
The Closures segment’s sales increased 5% to $181 million. The reported figure beat our estimate of $177 million. While product volumes improved, core sales were flat because results were weighed down by the pass-through of lower resin pricing.
Margins were notably weaker in the segment. Adjusted EBITDA fell to $23.6 million compared with the prior-year quarter’s $27 million, driven by maintenance issues and temporary plant closures tied to extreme weather in North America, as well as certain investment write-offs. We predicted the segment’s adjusted EBITDA to be $28 million.
AptarGroup’s Profit Picture Shows Margin Compression
On a reported basis, diluted earnings per share were $1.12 compared with $1.17 in the year-ago quarter. Operating income decreased to $107.5 million from $113.4 million as higher costs, and heavier depreciation and amortization weighed on results.
Adjusted EBITDA totaled $183 million compared with $189 million a year ago, translating to an adjusted EBITDA margin of 19.2%, down from the prior-year quarter’s 20.7%.
Story Continues
ATR’s Balance Sheet Updates
AptarGroup ended the quarter with cash and equivalents of $222.5 million, down from $402 million at the end of 2025. Net cash provided by operating activities increased to $119 million from $83 million in the prior-year quarter.
Capital allocation remained shareholder-friendly. ATR repurchased 707 thousand shares for $100 million, returning $131 million to shareholders. The company’s consolidated leverage ratio stood at 1.43 at the quarter-end.
AptarGroup’s Q2 View Points to Broader-Based Growth
For the second quarter of 2026, the company expects adjusted earnings per share of $1.32-$1.40.
Looking beyond the near term, AptarGroup expects 2026 capital investments of $260-$280 million, with most allocated to Pharma, and depreciation and amortization of $310-$320 million.
ATR Stock’s Price Performance
The company’s shares have lost 18.4% in the past year compared with the industry’s 8.7% decline.Zacks Investment Research
Image Source: Zacks Investment Research
AptarGroup’s Zacks Rank
ATR currently has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Recent Performances of ATR’s Peers
Sonoco Products Company SON delivered adjusted earnings of $1.20 per share in the first quarter of fiscal 2026, topping the Zacks Consensus Estimate of $1.19 by 0.84%. The figure declined 13% from $1.38 in the year-ago quarter.
Sonoco’s net sales were $1.68 billion, declining 1.9% year over year and lagging the Zacks Consensus Estimate of $1.71 billion by 1.95%. Pricing actions and productivity were key offsets to softer volume/mix during the quarter. SON’s top line dipped from the prior-year period primarily due to the absence of sales from the ThermoSafe temperature-assured packaging business, which was divested in November 2025.
Packaging Corporation of America PKG posted adjusted earnings of $2.40 per share in the first quarter of 2026, up 3.9% from $2.31 a year ago. Packaging Corp’s results beat the Zacks Consensus Estimate of earnings $2.17 by 10.6%.
Net sales rose 10.6% year over year to $2.37 billion but missed the consensus mark of $2.41 billion by 1.9%. Favorable pricing and mix, along with lower fiber costs, supported Packaging Corp’s results, though special items weighed on reported profitability.
Avery Dennison Corporation AVY registered adjusted earnings of $2.47 per share for the first quarter of 2026, rising 7.4% from the year-ago period and beating the Zacks Consensus Estimate of $2.41. Avery Dennison’s revenues were $2.298 billion, growing 7% year over year and surpassing the consensus mark of $2.271 billion by 1.2%.
Sales advanced 2.3%, excluding currency, as a 4.7% foreign-currency headwind weighed on reported growth. Organic sales increased 1.1%, while acquisitions were a 1.2% drag on the quarter’s growth bridge.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Sonoco Products Company (SON) : Free Stock Analysis Report
Avery Dennison Corporation (AVY) : Free Stock Analysis Report
Packaging Corporation of America (PKG) : Free Stock Analysis Report
AptarGroup, Inc. (ATR) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
View Comments
- AptarGroup Q1 Earnings Beat Estimates but Decline Y/Y, Shares Dip 1%
May 6, 2026 · zacks.com
ATR tops Q1 earnings estimates on strong sales growth, but profit declines, pharma headwinds and margin pressure send shares down despite an upbeat Q2 outlook.
- Advanced Technology Recycling (ATR) Announces That They Are Now Offering Wholesale Electronics to the General Public Through Their Online Auction Site
May 4, 2026 · globenewswire.com
ITAD Firm, Advanced Technology Recycling (ATR), now offers wholesale electronics and computers to the general public through our online auction platform.
- ADVANCED TECHNOLOGY RECYCLING (ATR) ANNOUNCES THAT THEY ARE NOW OFFERING WHOLESALE ELECTRONICS TO THE GENERAL PUBLIC THROUGH THEIR ONLINE AUCTION SITE
May 4, 2026
ITAD FIRM, ADVANCED TECHNOLOGY RECYCLING (ATR), NOW OFFERS WHOLESALE ELECTRONICS AND COMPUTERS TO THE GENERAL PUBLIC THROUGH OUR ONLINE AUCTION PLATFORM.
- Earnings Update: AptarGroup, Inc. (NYSE:ATR) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts
May 3, 2026
Shareholders might have noticed that AptarGroup, Inc. (NYSE:ATR) filed its quarterly result this time last week. The early response was not positive, with shares down 4.1% to US$119 in the past week. It was a workmanlike result, with revenues of US$983m coming in 2.8% ahead of expectations, and statutory earnings per share of US$1.12, in line with analyst appraisals. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. Readers will be glad to know we've aggregated the latest statutory forecasts to see whether the analysts have changed their mind on AptarGroup after the latest results.
AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.NYSE:ATR Earnings and Revenue Growth May 3rd 2026
After the latest results, the seven analysts covering AptarGroup are now predicting revenues of US$3.97b in 2026. If met, this would reflect a modest 2.6% improvement in revenue compared to the last 12 months. Statutory earnings per share are expected to shrink 9.2% to US$5.51 in the same period. Yet prior to the latest earnings, the analysts had been anticipated revenues of US$3.94b and earnings per share (EPS) of US$5.30 in 2026. So the consensus seems to have become somewhat more optimistic on AptarGroup's earnings potential following these results.
Check out our latest analysis for AptarGroup
The consensus price target was unchanged at US$163, implying that the improved earnings outlook is not expected to have a long term impact on value creation for shareholders. Fixating on a single price target can be unwise though, since the consensus target is effectively the average of analyst price targets. As a result, some investors like to look at the range of estimates to see if there are any diverging opinions on the company's valuation. The most optimistic AptarGroup analyst has a price target of US$220 per share, while the most pessimistic values it at US$144. These price targets show that analysts do have some differing views on the business, but the estimates do not vary enough to suggest to us that some are betting on wild success or utter failure.
One way to get more context on these forecasts is to look at how they compare to both past performance, and how other companies in the same industry are performing. The period to the end of 2026 brings more of the same, according to the analysts, with revenue forecast to display 3.4% growth on an annualised basis. That is in line with its 4.0% annual growth over the past five years. Juxtapose this against our data, which suggests that other companies (with analyst coverage) in the industry are forecast to see their revenues grow 3.7% per year. So although AptarGroup is expected to maintain its revenue growth rate, it's only growing at about the rate of the wider industry.
Story Continues
The Bottom Line
The most important thing here is that the analysts upgraded their earnings per share estimates, suggesting that there has been a clear increase in optimism towards AptarGroup following these results. They also reconfirmed their revenue estimates, with the company predicted to grow at about the same rate as the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.
Following on from that line of thought, we think that the long-term prospects of the business are much more relevant than next year's earnings. We have forecasts for AptarGroup going out to 2028, and you can see them free on our platform here.
Plus, you should also learn about the 2 warning signs we've spotted with AptarGroup .
Have feedback on this article? Concerned about the content?Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
View Comments
- AptarGroup Inc (ATR) Q1 2026 Earnings Call Highlights: Strong Sales Growth Amid Operational ...
May 2, 2026
This article first appeared on GuruFocus.
Reported Sales Increase: 11% increase in reported sales. Core Sales: Flat compared to the prior year, adjusting for currency effects and acquisitions. Adjusted EBITDA: $189 million, a 3% increase from the prior year. Adjusted EBITDA Margin: 19.2%, down from 20.7% in the prior year. Adjusted Earnings Per Share: $1.19, compared to $1.30 in the prior year at comparable exchange rates. Pharma Segment Core Sales: Decreased 1%, with a 3% negative impact from emergency medicine dispensing systems. Consumer Healthcare Core Sales: Increased 4%. Injectables Core Sales: Increased 20%. Beauty Segment Core Sales: Increased 3%. Personal Care Core Sales: Increased 6%. Closure Segment Core Sales: Flat compared to the prior year. Consolidated Gross Margins: Declined by 210 basis points year over year. SG&A as a Percentage of Sales: Decreased from 17.5% to 17.1% year over year. Free Cash Flow: $53 million for the quarter. Share Repurchases and Dividends: $100 million in share repurchases and $31 million in dividends paid. Cash Balance: $223 million as of March 31. Net Debt: $1.1 billion. Leverage Ratio: 1.43. Q2 Adjusted EPS Outlook: $1.32 to $1.40 per share. Full Year 2026 Capital Investments: Expected to be $260 million to $280 million. Depreciation and Amortization Expense: Expected to be $310 million to $320 million for the full year 2026.
Warning! GuruFocus has detected 2 Warning Sign with BAFN. Is ATR fairly valued? Test your thesis with our free DCF calculator.
Release Date: May 01, 2026
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
AptarGroup Inc (NYSE:ATR) reported an 11% increase in sales, with core sales remaining flat after adjusting for currency effects and acquisitions. The Pharma segment showed strong demand in injectables, with a 20% increase in core sales, driven by elastomeric components for GLP-1 biologics and antithrombotics. Consumer Healthcare core sales increased by 4%, supported by growth in eyecare and nasal decongestant products. The Beauty segment saw a 3% increase in core sales, with strong demand for prestige fragrance pumps and color cosmetics. AptarGroup Inc (NYSE:ATR) maintained a strong balance sheet, ending the quarter with a cash balance of $223 million and a leverage ratio of 1.43.
Negative Points
Pharma segment's core sales decreased by 1% due to less favorable product mix and a decline in emergency medicine sales. Adjusted EBITDA margin declined to 19.2% from 20.7% in the prior year, primarily due to less favorable product mix and operational challenges in beauty and closures. The Closures segment experienced a 270 basis point decline in adjusted EBITDA margin due to maintenance issues and temporary plant closures caused by extreme weather conditions. Adjusted earnings per share decreased to $1.19 from $1.30 in the prior year, impacted by higher depreciation, amortization expenses, and interest expenses. The company faced ongoing litigation with ARS Pharmaceuticals, which continues to progress and adds legal expenses.
Story Continues
Q & A Highlights
Q: With the recent approvals for neffy in the US and Canada, do you have increased visibility for 2026? A: Stephan Tanda, President and CEO, explained that while these approvals are positive, they do not significantly impact quarterly or annual results. However, they reinforce confidence in prescription growth for the remainder of the year, excluding emergency medicine.
Q: Are you expanding GLP-1 capacity in the elastomer business? A: Stephan Tanda confirmed that substantial investments have been made, and there is ample capacity with the potential to increase by adding more equipment in existing facilities.
Q: How do you expect the Rx component to perform in Q2 given the tough comparisons? A: Stephan Tanda stated that despite challenging comparisons, they expect solid growth in the Rx segment for Q2, excluding emergency medicine.
Q: Are there any supply chain uncertainties or prebuying trends affecting your business? A: Stephan Tanda noted limited prebuying due to high demand, and Gael Touya, President of Aptar Pharma, mentioned that consumer healthcare is on a positive trend with strong demand in ophthalmic and dermal drugs.
Q: Can you provide an update on the closures segment and when margins might normalize? A: Stephan Tanda and Vanessa Kanu, CFO, indicated that they expect closures margins to improve in the second half of the year, despite challenges from maintenance issues and weather-related disruptions.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
View Comments
